Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. University of Munich, Munich, Germany

Survival: 35.6 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: Germany
City/State/Province: Munich
Hospital: University of Munich
Journal: Link
Date: 8/2010

This phase II study involved 42 women with HER2-overexpressing metastatic breast cancer. The median age was 60 years, with a range of 34-75.

Patients were treated with vinorelbine, a chemotherapy agent that blocks cancer cell division (growth). This drug was given intravenously and orally. In addition, the biologic therapy trastuzumab was administered, which is an antibody that targets the HER2 protein on cancer cells and leads to cell death.

There were two deaths reported in this study but both were reported as not being asssociated with study treatment. Grade 4 neutropenia was experienced by 17% of patients. Other toxicities included grade 1-3 diarrhea (64% of patients), grade 1-4 elevated liver enzymes (52%), and grade 1-3 nausea (60%).

The median overall survival in this study was 35.6 months.

This study was supported by Pierre Fabre Pharma, the makers of oral vinorelbine (trade name Navelbine).

Correspondence: Dr. Volker Heinemann; email:

E-mail to a Friend Email Physician More Information